JMP Securities Increases Axon Enterprise (NASDAQ:AXON) Price Target to $430.00

Axon Enterprise (NASDAQ:AXON) had its price objective boosted by JMP Securities from $375.00 to $430.00 in a research report issued on Thursday, Marketbeat reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. JMP Securities’ target price points to a potential upside of 13.27% from the company’s current price.

A number of other research analysts have also weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price objective for the company. Bank of America assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price objective on the stock. Robert W. Baird lifted their target price on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. Finally, Craig Hallum raised their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $365.38.

Axon Enterprise Stock Performance

AXON stock opened at $379.61 on Thursday. The business has a 50 day moving average of $338.92 and a 200-day moving average of $314.35. The firm has a market cap of $28.69 billion, a PE ratio of 111.00, a P/E/G ratio of 9.69 and a beta of 0.94. Axon Enterprise has a 12-month low of $189.12 and a 12-month high of $385.00. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s revenue was up 34.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.80 EPS. As a group, sell-side analysts expect that Axon Enterprise will post 1.79 earnings per share for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the transaction, the chief financial officer now directly owns 98,825 shares in the company, valued at $37,449,733.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the sale, the chief financial officer now directly owns 98,825 shares in the company, valued at $37,449,733.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Joshua Isner sold 25,811 shares of Axon Enterprise stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total value of $9,287,830.24. Following the completion of the transaction, the president now owns 228,166 shares in the company, valued at approximately $82,103,253.44. The disclosure for this sale can be found here. Insiders sold 316,981 shares of company stock worth $115,281,744 in the last quarter. 6.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Dorsey Wright & Associates lifted its holdings in Axon Enterprise by 0.3% in the second quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock worth $4,135,000 after buying an additional 39 shares during the period. Avantax Advisory Services Inc. boosted its position in shares of Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after purchasing an additional 40 shares in the last quarter. Brookstone Capital Management grew its stake in Axon Enterprise by 5.1% in the first quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 41 shares during the period. Envestnet Portfolio Solutions Inc. raised its holdings in Axon Enterprise by 1.1% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,997 shares of the biotechnology company’s stock worth $1,033,000 after purchasing an additional 43 shares in the last quarter. Finally, CWM LLC lifted its position in Axon Enterprise by 1.5% during the second quarter. CWM LLC now owns 2,820 shares of the biotechnology company’s stock valued at $830,000 after buying an additional 43 shares during the period. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.